LuciAcor
LuciAcor is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular related hospitalization
Product details
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use LuciAcor safely and effectively. See full prescribing information for LuciAcor.
INDICATIONS AND USAGE
LuciAcor is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular related hospitalization.
DOSAGE AND ADMINISTRATION
The recommended dosage of LuciAcor is 712 mg orally twice daily.
DOSAGE FORMS AND STRENGTHS
Tablets: 356 mg×56 tablets
CONTRAINDICATIONS
None
Storage
Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from moisture.
Reviews
There are no reviews yet.